Related Experiment Video
Updated: Jan 11, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Autophagy in the Pathogenesis of Membranous Nephropathy
Claudio Ponticelli1, Francesco Reggiani2,3, Gabriella Moroni2,3
1Independent investigator, Milan, Italy.
Abstract:
Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults. In most cases, its etiology is unknown (idiopathic), while ∼30% of cases are secondary to other diseases, infections, or exposure to drugs and toxic agents. Up to 70% of patients with idiopathic MN have circulating antibodies against the M-type phospholipase A2 receptor, a podocyte surface protein. The formation of immune complexes on podocytes triggers complement activation, leading to the activation of both the C5b-C9 complex and C5a. Recently, several novel podocyte antigens have been identified in both idiopathic and secondary MN. Autophagy, a cellular mechanism that removes and recycles damaged cytoplasmic material, may have a dual role in MN pathogenesis. It can regulate innate and adaptive immune responses, promoting the production of autoantibodies against podocyte antigens. However, autophagy also protects podocytes from apoptosis and injury. In addition, it plays a role in the progression of tubular atrophy and interstitial fibrosis, which can lead to chronic kidney disease and kidney failure. This article explores the mechanisms that activate and regulate macroautophagy and examines its role in MN. The potential therapeutic implications of autophagy regulation in MN, based on preliminary studies, are also discussed.
Insights
Membranous nephropathy (MN) involves immune attacks on podocytes. Autophagy, a cellular process, plays a complex role in MN, potentially driving autoantibody production but also offering podocyte protection and influencing disease progression.
Area of Science:
- Nephrology
- Immunology
- Cell Biology
Background:
- Membranous nephropathy (MN) is a primary cause of nephrotic syndrome in adults, often idiopathic.
- Antibodies against podocyte proteins, like the M-type phospholipase A2 receptor, are implicated in MN pathogenesis.
- Autophagy, a cellular degradation process, has a potentially dual role in MN.
Purpose of the Study:
- To explore the mechanisms regulating macroautophagy in the context of MN.
- To examine the specific role of autophagy in the pathogenesis and progression of MN.
- To discuss the therapeutic potential of modulating autophagy in MN.
Main Methods:
- Review of current literature on autophagy mechanisms and MN.
- Analysis of the dual role of autophagy in immune response and podocyte injury.
- Exploration of preliminary studies on autophagy modulation for MN treatment.
Main Results:
- Autophagy can influence immune responses, potentially promoting autoantibody production against podocyte antigens.
- Autophagy also confers protective effects on podocytes, mitigating apoptosis and injury.
- Autophagy is involved in the progression of tubulointerstitial fibrosis, contributing to chronic kidney disease.
Conclusions:
- Autophagy has a complex, context-dependent role in membranous nephropathy.
- Understanding autophagy regulation is crucial for developing novel therapeutic strategies for MN.
- Targeting autophagy may offer a promising avenue for treating MN and preventing kidney failure.
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Lysosomal Hydrolases
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

